172 related articles for article (PubMed ID: 27794567)
1. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
[TBL] [Abstract][Full Text] [Related]
2. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
Jiménez-Ruiz CA; Solano-Reina S; Signes-Costa J; de Higes-Martinez E; Granda-Orive JI; Lorza-Blasco JJ; Riesco-Miranda JA; Altet-Gomez N; Barrueco M; Oyagüez I; Rejas J;
Int J Chron Obstruct Pulmon Dis; 2015; 10():2027-36. PubMed ID: 26451100
[TBL] [Abstract][Full Text] [Related]
3. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
Rejas-Gutiérrez J; Bruguera E; Cedillo S
Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
8. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
von Wartburg M; Raymond V; Paradis PE
Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease.
Kirsch F
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):301-16. PubMed ID: 25600470
[TBL] [Abstract][Full Text] [Related]
12. Budgetary impact of varenicline in smoking cessation in the United Kingdom.
Taylor DC; Chu P; Rosen VM; Baker CL; Thompson D
Value Health; 2009; 12(1):28-33. PubMed ID: 18637141
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
[TBL] [Abstract][Full Text] [Related]
14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
15. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
Atsou K; Chouaid C; Hejblum G
PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.
Paradis PE; Mishagina N; Carter V; Raymond V
Healthc Q; 2012; 15(2):52-60. PubMed ID: 22688206
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment with varenicline is a cost-effective aid for smoking cessation.
Kautiainen K; Ekroos H; Puhakka M; Liira H; Laine J; Linden K; Hahl J
J Med Econ; 2017 Mar; 20(3):246-252. PubMed ID: 27754739
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients.
Christenhusz LC; Prenger R; Pieterse ME; Seydel ER; van der Palen J
Nicotine Tob Res; 2012 Jun; 14(6):657-63. PubMed ID: 22180589
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
Knight C; Howard P; Baker CL; Marton JP
Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.
Igarashi A; Takuma H; Fukuda T; Tsutani K
Pharmacoeconomics; 2009; 27(3):247-61. PubMed ID: 19354344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
